These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 9632118)

  • 1. Immunochemical quantification of crossline as a fluorescent advanced glycation endproduct in erythrocyte membrane proteins from diabetic patients with or without retinopathy.
    Yamaguchi M; Nakamura N; Nakano K; Kitagawa Y; Shigeta H; Hasegawa G; Ienaga K; Nakamura K; Nakazawa Y; Fukui I; Obayashi H; Kondo M
    Diabet Med; 1998 Jun; 15(6):458-62. PubMed ID: 9632118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crossline levels in serum and erythrocyte membrane proteins from patients with diabetic nephropathy.
    Aoki S; Hasegawa G; Shigeta H; Obayashi H; Fujii M; Kimura F; Moriwaki A; Nakamura N; Ienaga K; Nakamura K; Kondo M
    Diabetes Res Clin Pract; 2000 May; 48(2):119-25. PubMed ID: 10802149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo.
    Obayashi H; Nakano K; Shigeta H; Yamaguchi M; Yoshimori K; Fukui M; Fujii M; Kitagawa Y; Nakamura N; Nakamura K; Nakazawa Y; Ienaga K; Ohta M; Nishimura M; Fukui I; Kondo M
    Biochem Biophys Res Commun; 1996 Sep; 226(1):37-41. PubMed ID: 8806589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel advanced glycation index and its association with diabetes and microangiopathy.
    Sampathkumar R; Balasubramanyam M; Rema M; Premanand C; Mohan V
    Metabolism; 2005 Aug; 54(8):1002-7. PubMed ID: 16092048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased protein carbonylation of red blood cell membrane in diabetic retinopathy.
    Margetis PI; Antonelou MH; Petropoulos IK; Margaritis LH; Papassideri IS
    Exp Mol Pathol; 2009 Aug; 87(1):76-82. PubMed ID: 19379730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications.
    Ono Y; Aoki S; Ohnishi K; Yasuda T; Kawano K; Tsukada Y
    Diabetes Care; 1998 Jun; 21(6):1027. PubMed ID: 9614627
    [No Abstract]   [Full Text] [Related]  

  • 7. Products of advanced glycation in patients with type 2 diabetes and vascular disease.
    Turk Z; Sesto M; Skodlar J; Ferencak G; Pokupec R; Turk N; Stavljenić-Rukavina A
    Ann Clin Biochem; 2003 Sep; 40(Pt 5):552-9. PubMed ID: 14503994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy.
    Kakehashi A; Inoda S; Mameuda C; Kuroki M; Jono T; Nagai R; Horiuchi S; Kawakami M; Kanazawa Y
    Diabetes Res Clin Pract; 2008 Mar; 79(3):438-45. PubMed ID: 18053608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The change of oxidative stress products in diabetes mellitus and diabetic retinopathy.
    Pan HZ; Zhang H; Chang D; Li H; Sui H
    Br J Ophthalmol; 2008 Apr; 92(4):548-51. PubMed ID: 18369071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease.
    Koga H; Sugiyama S; Kugiyama K; Watanabe K; Fukushima H; Tanaka T; Sakamoto T; Yoshimura M; Jinnouchi H; Ogawa H
    J Am Coll Cardiol; 2005 May; 45(10):1622-30. PubMed ID: 15893178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced glycation end products in vitreous: Structural and functional implications for diabetic vitreopathy.
    Stitt AW; Moore JE; Sharkey JA; Murphy G; Simpson DA; Bucala R; Vlassara H; Archer DB
    Invest Ophthalmol Vis Sci; 1998 Dec; 39(13):2517-23. PubMed ID: 9856760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Changes of plasma endothelin-1 and vascular endothelial growth factor in diabetic retinopathy and the clinical application value thereof].
    Zhu H; Shi CH
    Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(40):2837-9. PubMed ID: 18167288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of adrenomedullin, a vasoactive peptide, in type 2 diabetic patients with and without retinopathy.
    Caliumi C; Balducci S; Petramala L; Cotesta D; Zinnamosca L; Cianci R; Di Donato D; Vingolo EM; Fallucca F; Letizia C
    Minerva Endocrinol; 2007 Jun; 32(2):73-8. PubMed ID: 17557032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severity of diabetic microvascular complications is associated with a low soluble RAGE level.
    Grossin N; Wautier MP; Meas T; Guillausseau PJ; Massin P; Wautier JL
    Diabetes Metab; 2008 Sep; 34(4 Pt 1):392-5. PubMed ID: 18701333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The - 429 T/C and - 374 T/A gene polymorphisms of the receptor of advanced glycation end products gene are not risk factors for diabetic retinopathy in Caucasians with type 2 diabetes.
    Globocnik Petrovic M; Steblovnik K; Peterlin B; Petrovic D
    Klin Monbl Augenheilkd; 2003 Dec; 220(12):873-6. PubMed ID: 14704946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of serum semicarbazide-sensitive amine oxidase activity in diabetic retinopathy in type-2 diabetes].
    Dura E; Mészáros Z; Salacz G; Magyar K; Romics L; Karádi I
    Orv Hetil; 2002 Nov; 143(47):2637-44. PubMed ID: 12532650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes.
    Gardiner TA; Anderson HR; Stitt AW
    J Pathol; 2003 Oct; 201(2):328-33. PubMed ID: 14517851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythrocyte membrane anionic content and urinary glycosaminoglycan excretion in type 1 diabetes: association with retinopathy.
    Yenice O; Kazokoğlu H; Ozcan E; Yüksel M; Adigüzel G; Haklar G; Yavuz DG
    Curr Eye Res; 2006 Nov; 31(11):975-81. PubMed ID: 17114123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Diabetes Metab Res Rev; 2008 Feb; 24(2):109-14. PubMed ID: 17694504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.
    Nakamura K; Yamagishi S; Adachi H; Matsui T; Kurita-Nakamura Y; Takeuchi M; Inoue H; Imaizumi T
    Microvasc Res; 2008 May; 76(1):52-6. PubMed ID: 18474381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.